Regulatory matrix

91 published regulatory records. Each cites an official source and the date it was checked. A regulatory status says what one regulator recorded for one scope. It is not evidence of efficacy or safety, and one jurisdiction’s action does not apply in another. Pairs marked “No published record” mean only that WPF has published nothing for that jurisdiction. They do not mean no regulatory action exists or that a review is scheduled. Product or formulation is shown as “Not recorded” because the record does not capture it. The action label comes from the linked official source, not from the jurisdiction name.

Download filtered CSV

414 rows

Regulatory records by peptide and jurisdiction
PeptideJurisdictionRegulatorProduct or formulationScopeActionLinked sourceDate checked
AOD-9604European Union (EMA)EMANot recordedNo centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-08
AOD-9604United States (FDA)FDANot recordedNo FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.No approval recordedDrugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov2026-09-08
AbaloparatideEuropean Union (EMA)EMANot recordedELADYNOS (abaloparatide) is centrally authorised in the European Union for treatment of osteoporosis in postmenopausal women at increased risk of fracture.Approval recordedEMA EPAR — Eladynos (EMEA/H/C/005928)Linked source: www.ema.europa.eu2026-09-09
AbaloparatideUnited States (FDA)FDANot recordedTYMLOS (abaloparatide) is FDA-approved for treatment of postmenopausal women with osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy, and to increase bone density in men with osteoporosis at high risk for fracture or with the same treatment-history criteria.Approval recordedFDA Drugs@FDA NDA 208743 and TYMLOS Prescribing Information, revised August 2026Linked source: www.accessdata.fda.gov2026-09-09
AfamelanotideEuropean Union — EMAEMANot recordedScenesse (afamelanotide) is indicated for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).Approval recordedEuropean Medicines Agency: Scenesse (afamelanotide)Linked source: www.ema.europa.eu2026-09-23
AfamelanotideUnited States — FDAFDANot recordedSCENESSE (afamelanotide) is indicated to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).Approval recordedFDA Orphan Drug Designations and Approvals: afamelanotide / SCENESSELinked source: www.accessdata.fda.gov2026-09-23
BPC-157European Union (EMA)EMANot recordedNo centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-08
BPC-157United States (FDA)FDANot recordedNo FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.No approval recordedDrugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov2026-09-08
BivalirudinEuropean Union (EMA)EMANot recordedAngiox (bivalirudin) previously held an EU marketing authorization for adult PCI and urgent or early intervention in unstable angina or NSTEMI with specified concomitant antiplatelet therapy. The European Commission withdrew the authorization on 21 June 2018 at the marketing-authorization holder’s request for commercial discontinuation; the authorization is no longer valid. This is a withdrawal record, not a finding that the medicine lacked efficacy or safety.No approval recordedEMA EPAR — Angiox: withdrawn marketing authorisationLinked source: www.ema.europa.eu2026-09-09
BivalirudinUnited States (FDA)FDANot recordedANGIOMAX (bivalirudin) is FDA-approved as an intravenous anticoagulant for patients undergoing percutaneous coronary intervention, including patients with heparin-induced thrombocytopenia or heparin-induced thrombocytopenia and thrombosis syndrome.Approval recordedFDA Drugs@FDA NDA 020873 and ANGIOMAX Prescribing InformationLinked source: www.accessdata.fda.gov2026-09-09
BremelanotideEuropean Union — EMAEMANot recordedNo centrally authorized EMA medicine containing bremelanotide was identified in the EMA medicines database as of 2026-09-23. Palatin Technologies licensed European rights for bremelanotide to Gedeon Richter in 2014; that licensing agreement was terminated in September 2016 with no EU marketing authorization resulting. Bremelanotide (Vyleesi) is FDA-approved in the United States only. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-23
BremelanotideUnited States — FDAFDANot recordedVYLEESI (bremelanotide) is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty, and not due to a co-existing medical or psychiatric condition, relationship problems, or the effects of a medication or drug substance. Not indicated for HSDD in postmenopausal women or in men.Approval recordedFDA VYLEESI (bremelanotide injection) prescribing informationLinked source: www.accessdata.fda.gov2026-09-23
CJC-1295European Union (EMA)EMANot recordedNo centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-08
CJC-1295United States (FDA)FDANot recordedNo FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.No approval recordedDrugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov2026-09-08
CagrilintideEuropean Union — EMAEMANot recordedNo centrally authorized EMA medicine containing cagrilintide was identified in the EMA medicines database as of 2026-09-23. Cagrilintide remains investigational and has not completed EU marketing review. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-23
CagrilintideUnited States — FDAFDANot recordedNo FDA-approved product containing cagrilintide was identified in the FDA Drugs@FDA database as of 2026-09-23. Cagrilintide remains investigational, including in combination with semaglutide (CagriSema), and has not completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific.No approval recordedFDA Drugs@FDA databaseLinked source: www.accessdata.fda.gov2026-09-23
CarbetocinAustralia (TGA)TGANot recordedDURATOCIN carbetocin 100 microgram/mL injection is entered in the Australian Register of Therapeutic Goods for prevention of uterine atony and excessive bleeding following delivery in the product-specified obstetric setting.Approval recordedTGA ARTG — DURATOCIN carbetocin 100 microgram/mL injection vialLinked source: www.tga.gov.au2026-09-09
CarbetocinCanada (Health Canada)Health CanadaNot recordedDURATOCIN (carbetocin injection) is authorized in Canada for prevention of uterine atony and postpartum haemorrhage in the labeled obstetric setting.Approval recordedHealth Canada Product Monograph — DURATOCIN (carbetocin injection)Linked source: health-products.canada.ca2026-09-09
DesmopressinUnited States (FDA — DDAVP)FDANot recordedDDAVP desmopressin acetate tablets are FDA-approved as antidiuretic replacement therapy in central diabetes insipidus and for management of temporary polyuria and polydipsia following head trauma or pituitary-region surgery, subject to current labeling.Approval recordedFDA Drugs@FDA — DDAVP NDA 019955Linked source: www.accessdata.fda.gov2026-09-09
DesmopressinUnited States (FDA — DESMODA)FDANot recordedDESMODA desmopressin acetate oral solution is FDA-approved for antidiuretic replacement therapy in patients with central diabetes insipidus (arginine vasopressin deficiency), according to its current product labeling.Approval recordedFDA Drugs@FDA — DESMODA NDA 219873Linked source: www.accessdata.fda.gov2026-09-09
ElamipretideEuropean UnionEMANot recordedEMA orphan designation is not marketing authorization; no EU marketing authorization was identified in the reviewed official record.No approval recordedEMA orphan designation EU/3/21/2430Linked source: www.ema.europa.eu2026-09-09
ElamipretideUnited StatesFDANot recordedImprove muscle strength in adults and pediatric patients with Barth syndrome weighing at least 30 kg.Approval recordedFDA accelerated approval announcementLinked source: www.fda.gov2026-09-09
EpitalonEuropean Union (EMA)EMANot recordedNo centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-08
EpitalonUnited States (FDA)FDANot recordedNo FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.No approval recordedDrugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov2026-09-08
GHRP-2European UnionEMANot recordedNo marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck.No approval recordedEMA medicines portalLinked source: www.ema.europa.eu2026-09-09
GHRP-2United StatesFDANot recordedNo marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck.No approval recordedFDA Drugs@FDA / official FDA recordLinked source: www.accessdata.fda.gov2026-09-09
GHRP-6European UnionEMANot recordedNo marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck.No approval recordedEMA medicines portalLinked source: www.ema.europa.eu2026-09-09
GHRP-6United StatesFDANot recordedNo marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck.No approval recordedFDA Drugs@FDA / official FDA recordLinked source: www.accessdata.fda.gov2026-09-09
GlucagonEuropean Union — EMAEMANot recordedBaqsimi (glucagon nasal powder) is centrally authorized for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.Approval recordedEuropean Medicines Agency: Baqsimi (glucagon)Linked source: www.ema.europa.eu2026-09-23
GlucagonUnited States — FDAFDANot recordedGlucaGen (glucagon), specifically -- not glucagon as a class: indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes, and separately indicated as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal tract movement in adult patients only.Approval recordedFDA GlucaGen (glucagon) prescribing informationLinked source: www.accessdata.fda.gov2026-09-23
HexarelinEuropean UnionEMANot recordedNo marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck.No approval recordedEMA medicines portalLinked source: www.ema.europa.eu2026-09-09
HexarelinUnited StatesFDANot recordedNo marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck.No approval recordedFDA Drugs@FDA / official FDA recordLinked source: www.accessdata.fda.gov2026-09-09
Human chorionic gonadotropin (hCG)European UnionEMANot recordedAuthorized products exist; exact product, indication, contraindications, and current labeling require owner verification.Approval recordedEMA medicines portalLinked source: www.ema.europa.eu2026-09-09
Human chorionic gonadotropin (hCG)United StatesFDANot recordedAuthorized products exist; exact product, indication, contraindications, and current labeling require owner verification.Approval recordedFDA Drugs@FDA / official FDA recordLinked source: www.accessdata.fda.gov2026-09-09
HumaninEuropean Union — EMAEMANot recordedNo centrally authorized EMA medicine containing humanin was identified in the EMA medicines database as of 2026-09-23. Humanin remains an investigational research-stage compound with no completed EU marketing review. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-23
HumaninUnited States — FDAFDANot recordedNo FDA-approved product containing humanin was identified in the FDA Drugs@FDA database as of 2026-09-23. Humanin remains an investigational, laboratory- and animal-research-stage mitochondrial-derived peptide with no completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific.No approval recordedFDA Drugs@FDA databaseLinked source: www.accessdata.fda.gov2026-09-23
IpamorelinEuropean Union (EMA)EMANot recordedNo centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-08
IpamorelinUnited States (FDA)FDANot recordedNo FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.No approval recordedDrugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov2026-09-08
KPVEuropean Union (EMA)EMANot recordedNo centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-08
KPVUnited States (FDA)FDANot recordedNo FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.No approval recordedDrugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov2026-09-08
KisspeptinEuropean Union — EMAEMANot recordedNo centrally authorized EMA medicine containing kisspeptin was identified in the EMA medicines database as of 2026-09-23. Kisspeptin remains investigational with no completed EU marketing review. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-23
KisspeptinUnited States — FDAFDANot recordedNo FDA-approved product containing kisspeptin was identified in the FDA Drugs@FDA database as of 2026-09-23. Kisspeptin remains investigational, used chiefly as a research probe in reproductive-endocrinology studies, with no completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific.No approval recordedFDA Drugs@FDA databaseLinked source: www.accessdata.fda.gov2026-09-23
Kisspeptin-10European UnionEMANot recordedNo marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck.No approval recordedEMA medicines portalLinked source: www.ema.europa.eu2026-09-09
Kisspeptin-10United StatesFDANot recordedNo marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck.No approval recordedFDA Drugs@FDA / official FDA recordLinked source: www.accessdata.fda.gov2026-09-09
LL-37European UnionEMANot recordedNo marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck.No approval recordedEMA medicines portalLinked source: www.ema.europa.eu2026-09-09
LL-37United StatesFDANot recordedNo marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck.No approval recordedFDA Drugs@FDA / official FDA recordLinked source: www.accessdata.fda.gov2026-09-09
LanreotideUnited States (FDA — SOMATULINE DEPOT)FDANot recordedSOMATULINE DEPOT is FDA-approved for long-term treatment of acromegalic patients meeting label criteria, treatment of unresectable well- or moderately differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival, and treatment of carcinoid syndrome to reduce short-acting somatostatin-analog rescue therapy.Approval recordedFDA Drugs@FDA — SOMATULINE DEPOT NDA 022074Linked source: www.accessdata.fda.gov2026-09-09
LanreotideUnited States (FDA — lanreotide acetate)FDANot recordedFDA application NDA 215395 covers a currently marketed lanreotide acetate injection product in the strengths and indications specified by its approved labeling.Approval recordedFDA Drugs@FDA — Lanreotide acetate NDA 215395Linked source: www.accessdata.fda.gov2026-09-09
LeuprolideUnited States (FDA — LUPRON DEPOT)FDANot recordedLUPRON DEPOT leuprolide acetate is FDA-approved in product-specific depot formulations for palliative treatment of advanced prostate cancer and for other indications only as stated in the applicable current labeling.Approval recordedFDA Drugs@FDA — LUPRON DEPOT NDA 019943Linked source: www.accessdata.fda.gov2026-09-09
LeuprolideUnited States (FDA — LUPRON DEPOT-PED)FDANot recordedLUPRON DEPOT-PED is FDA-approved for treatment of pediatric patients with central precocious puberty under its age-, formulation-, dose-, and monitoring-specific labeling.Approval recordedFDA Drugs@FDA — LUPRON DEPOT-PED NDA 020263Linked source: www.accessdata.fda.gov2026-09-09
LinaclotideEuropean Union — EMAEMANot recordedConstella (linaclotide) is centrally authorized for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults.Approval recordedEuropean Medicines Agency: Constella (linaclotide)Linked source: www.ema.europa.eu2026-09-23
LinaclotideUnited States — FDAFDANot recordedLINZESS (linaclotide) is indicated for the treatment of: irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older; chronic idiopathic constipation (CIC) in adults; and functional constipation (FC) in pediatric patients 6 years of age and older. Contraindicated in patients less than 2 years of age (boxed warning: risk of serious dehydration).Approval recordedFDA LINZESS (linaclotide) prescribing informationLinked source: www.accessdata.fda.gov2026-09-23
MOTS-cEuropean Union (EMA)EMANot recordedNo centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-08
MOTS-cUnited States (FDA)FDANot recordedNo FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.No approval recordedDrugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov2026-09-08
MazdutideChina — NMPANMPANot recordedMazdutide injection is approved by China's National Medical Products Administration for chronic weight management in adults with obesity or overweight (NMPA approval date 2025-06-24; approval numbers 国药准字H20250036, 国药准字H20250037, 国药准字H20250038; the NMPA notice was published 2025-06-30). Indication wording (source: Innovent Biologics announcement of 2025-06-27, a company source and not the regulator; the announcement date is not the approval date): adjunct to a reduced-calorie diet and increased physical activity in adults with an initial BMI of 28 kg/m² or more (obesity), or 24 kg/m² or more (overweight) with at least one weight-related comorbid condition. Separately, a second indication, glycemic control in adults with type 2 diabetes, was announced as approved on 2025-09-19; that date rests on the company announcement and Chinese news reports, and no NMPA notice for it has been read.Approval recordedNMPA notice, published 2025-06-30: 2025年06月30日药品批准证明文件送达信息Linked source: www.nmpa.gov.cn2026-11-13
MazdutideUnited States — FDAFDANot recordedNo FDA-approved product containing mazdutide was identified in the FDA Drugs@FDA database as of 2026-09-23. Mazdutide is approved in China (see the China — NMPA entry on this profile) but remains investigational in the United States, where it has not completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific.No approval recordedFDA Drugs@FDA databaseLinked source: www.accessdata.fda.gov2026-09-23
Melanotan IIEuropean UnionEMANot recordedNo marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck.No approval recordedEMA medicines portalLinked source: www.ema.europa.eu2026-09-09
Melanotan IIUnited StatesFDANot recordedNo FDA marketing approval identified. FDA separately reports limited safety information and potential risks for compounded Melanotan II.Compounding actionFDA compounding safety-risk listLinked source: www.fda.gov2026-09-09
OctreotideUnited States (FDA — MYCAPSSA)FDANot recordedMYCAPSSA octreotide delayed-release capsules are FDA-approved for long-term maintenance treatment in acromegaly patients who responded to and tolerated octreotide or lanreotide, according to current labeling.Approval recordedFDA Drugs@FDA — MYCAPSSA NDA 208232Linked source: www.accessdata.fda.gov2026-09-09
OctreotideUnited States (FDA — SANDOSTATIN LAR DEPOT)FDANot recordedSANDOSTATIN LAR DEPOT is FDA-approved for long-term maintenance treatment in acromegaly after response and tolerance to subcutaneous octreotide, and for long-term treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and profuse watery diarrhea associated with VIP-secreting tumors, under current label criteria.Approval recordedFDA Drugs@FDA — SANDOSTATIN LAR DEPOT NDA 021008Linked source: www.accessdata.fda.gov2026-09-09
OxytocinUnited States (FDA — OXYTOCIN injection)FDANot recordedOxytocin injection under NDA 018248 is FDA-approved as a prescription injectable product for its labeled obstetric uses and strengths.Approval recordedFDA Drugs@FDA — OXYTOCIN NDA 018248Linked source: www.accessdata.fda.gov2026-09-10
OxytocinUnited States (FDA — PITOCIN)FDANot recordedPITOCIN oxytocin injection is FDA-approved for labeled obstetric uses, including medically indicated initiation or improvement of uterine contractions and control of postpartum uterine bleeding, subject to current labeling.Approval recordedFDA Drugs@FDA — PITOCIN NDA 018261Linked source: www.accessdata.fda.gov2026-09-10
PemvidutideEuropean Union — EMAEMANot recordedNo centrally authorized EMA medicine containing pemvidutide was identified in the EMA medicines database as of 2026-09-23. Pemvidutide remains investigational with no completed EU marketing review. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-23
PemvidutideUnited States — FDAFDANot recordedNo FDA-approved product containing pemvidutide was identified in the FDA Drugs@FDA database as of 2026-09-23. Pemvidutide (ALT-801) remains an investigational compound in clinical development, with no completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific.No approval recordedFDA Drugs@FDA databaseLinked source: www.accessdata.fda.gov2026-09-23
PramlintideEuropean Union — EMAEMANot recordedNo centrally authorized EMA medicine containing pramlintide was identified in the EMA medicines database as of 2026-09-23. Pramlintide (SYMLIN) is FDA-approved in the United States only. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-23
PramlintideUnited States — FDAFDANot recordedSYMLIN (pramlintide) is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy. Labeled pediatric use: safety and effectiveness in pediatric patients have not been established.Approval recordedFDA SYMLIN (pramlintide acetate) prescribing informationLinked source: www.accessdata.fda.gov2026-09-23
RetatrutideEuropean Union (EMA)EMANot recordedNo centrally authorised retatrutide medicine is listed. An EMA paediatric investigation plan is a development requirement and does not constitute marketing authorisation.No approval recordedEMA medicines database and retatrutide paediatric investigation planLinked source: www.ema.europa.eu2026-09-08
RetatrutideUnited States (FDA)FDANot recordedRetatrutide remains investigational and is not an FDA-approved drug. Substance identity records, clinical-trial status, or development announcements do not constitute marketing approval.No approval recordedFDA — concerns with unapproved GLP-1 drugs used for weight lossLinked source: www.fda.gov2026-09-08
SelankEuropean UnionEMANot recordedNo marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck.No approval recordedEMA medicines portalLinked source: www.ema.europa.eu2026-09-09
SelankUnited StatesFDANot recordedNo FDA marketing approval identified. FDA separately reports limited safety information and potential risks for compounded Selank.Compounding actionFDA compounding safety-risk listLinked source: www.fda.gov2026-09-09
SemaglutideEuropean Union (EMA)EMANot recordedSemaglutide is centrally authorised in the European Union in product-specific forms: Ozempic and Rybelsus for defined type 2 diabetes populations, and Wegovy for weight management in defined adults and adolescents. The applicable population, formulation, dose, contraindications, and current product information remain controlling.Approval recordedEMA EPARs — Wegovy, Ozempic and RybelsusLinked source: www.ema.europa.eu2026-09-08
SemaglutideUnited States (FDA)FDANot recordedCurrent FDA labeling for Wegovy identifies semaglutide formulations for defined cardiovascular-risk reduction and chronic weight-reduction populations; Wegovy injection is also approved for defined adults with noncirrhotic MASH and moderate-to-advanced fibrosis under accelerated approval. Product, formulation, age, comorbidity, and indication restrictions apply.Approval recordedFDA Wegovy Prescribing Information, revised June 2026Linked source: www.accessdata.fda.gov2026-09-08
SemaxEuropean UnionEMANot recordedNo marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck.No approval recordedEMA medicines portalLinked source: www.ema.europa.eu2026-09-09
SemaxUnited StatesFDANot recordedNo FDA marketing approval identified. FDA separately reports limited safety information and potential risks for compounded Semax.Compounding actionFDA compounding safety-risk listLinked source: www.fda.gov2026-09-09
TB-500European Union (EMA)EMANot recordedNo centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-08
TB-500United States (FDA)FDANot recordedNo FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.No approval recordedDrugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov2026-09-08
TeduglutideEuropean Union — EMAEMANot recordedRevestive (teduglutide) is indicated for the treatment of patients 4 months corrected gestational age and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery. (Per the current SmPC Section 4.1; supersedes the older '1 year and above' figure still shown in the EMA overview page's summary info box as of this research.)Approval recordedEuropean Medicines Agency: Revestive (teduglutide)Linked source: www.ema.europa.eu2026-09-23
TeduglutideUnited States — FDAFDANot recordedGATTEX (teduglutide) is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.Approval recordedFDA GATTEX (teduglutide) prescribing informationLinked source: www.accessdata.fda.gov2026-09-23
TeriparatideUnited States (FDA — BONSITY)FDANot recordedBONSITY teriparatide is FDA-approved as a prescription subcutaneous teriparatide product for its labeled osteoporosis indications and populations.Approval recordedFDA Drugs@FDA — BONSITY NDA 211939Linked source: www.accessdata.fda.gov2026-09-10
TeriparatideUnited States (FDA — FORTEO)FDANot recordedFORTEO teriparatide is FDA-approved for labeled osteoporosis indications in specified patients at high fracture risk; the current product, strength, route, duration guidance, warnings, and patient-selection language control.Approval recordedFDA Drugs@FDA — FORTEO NDA 021318Linked source: www.accessdata.fda.gov2026-09-10
TesamorelinUnited StatesFDANot recordedReduction of excess abdominal fat in adult patients with HIV and lipodystrophy.Approval recordedDrugs@FDA BLA 022505 and EGRIFTA prescribing informationLinked source: www.accessdata.fda.gov2026-09-08
Thymosin alpha-1European Union (EMA)EMANot recordedNo centrally authorized EMA thymosin alpha-1 or thymalfasin medicine was identified in the EMA medicines database as of 8 September 2026.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-08
Thymosin alpha-1United States (FDA)FDANot recordedNo FDA-approved thymosin alpha-1 or thymalfasin drug product or therapeutic indication was identified in Drugs@FDA as of 8 September 2026.No approval recordedDrugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov2026-09-08
Thymosin beta-4European Union — EMAEMANot recordedNo centrally authorized EMA medicine containing thymosin beta-4 was identified in the EMA medicines database as of 2026-09-23. Thymosin beta-4 remains an unapproved, investigational compound with no completed EU marketing review. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific.No approval recordedEuropean Medicines Agency medicines databaseLinked source: www.ema.europa.eu2026-09-23
Thymosin beta-4United States — FDAFDANot recordedNo FDA-approved product containing thymosin beta-4 was identified in the FDA Drugs@FDA database as of 2026-09-23. Thymosin beta-4 remains an unapproved, investigational compound with no completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific.No approval recordedFDA Drugs@FDA databaseLinked source: www.accessdata.fda.gov2026-09-23
TirzepatideEuropean Union (EMA)EMANot recordedMounjaro is centrally authorised in the European Union for defined type 2 diabetes and weight-management populations, subject to the current product information.Approval recordedEMA EPAR — MounjaroLinked source: www.ema.europa.eu2026-09-08
TirzepatideUnited States (FDA)FDANot recordedMounjaro is approved for defined patients with type 2 diabetes; Zepbound is approved for chronic weight management in defined adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. Product- and label-specific restrictions apply.Approval recordedFDA Drugs@FDA — tirzepatide (Mounjaro and Zepbound)Linked source: www.accessdata.fda.gov2026-09-08
VasopressinCanada (Health Canada — Vasopressin Injection USP DIN 02139502)Health CanadaNot recordedCanadian-authorized product: Vasopressin Injection, USP, 20 units/mL, for intramuscular or subcutaneous administration (DIN 02139502, Fresenius Kabi Canada Ltd). Its Health Canada product monograph (dated 2022-03-28) states it is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows, and in diabetes insipidus. Separate from this authorization, a Health Canada notice (last updated 2026-03-04) permits exceptional, temporary importation of a different, US-authorized product, Vasopressin Injection, USP, 20 units/mL for IV infusion (Fresenius Kabi USA, NDC 63323-930-00, listed under a US product code and not a Canadian DIN), during a shortage of the Canadian product.Approval recordedHealth Canada Drug Product Database: VASOPRESSIN INJECTION, USP, DIN 02139502 (Fresenius Kabi Canada Ltd), status MarketedLinked source: health-products.canada.ca2026-11-13
VasopressinUnited States (FDA — VASOSTRICT)FDANot recordedVASOSTRICT vasopressin intravenous solution is FDA-approved to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines, according to current labeling.Approval recordedFDA Drugs@FDA — VASOSTRICT NDA 204485Linked source: www.accessdata.fda.gov2026-09-10
ZiconotideEuropean Union — EMAEMANot recordedZiconotide (Prialt) is indicated for the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia.Approval recordedEuropean Medicines Agency: Prialt (ziconotide)Linked source: www.ema.europa.eu2026-09-23
ZiconotideUnited States — FDAFDANot recordedPRIALT (ziconotide intrathecal infusion) is indicated for the management of severe chronic pain in patients for whom intrathecal (IT) therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine. Labeled pediatric use: safety and effectiveness in pediatric patients have not been established.Approval recordedFDA PRIALT (ziconotide) prescribing informationLinked source: www.accessdata.fda.gov2026-09-23
AOD-9604United KingdomMHRANot recordedNot recordedNo published record——
AOD-9604CanadaHealth CanadaNot recordedNot recordedNo published record——
AOD-9604AustraliaTGANot recordedNot recordedNo published record——
AOD-9604JapanPMDA / MHLWNot recordedNot recordedNo published record——
AOD-9604ChinaNMPANot recordedNot recordedNo published record——
AOD-9604Sport (WADA)WADANot recordedNot recordedNo published record——
AbaloparatideUnited KingdomMHRANot recordedNot recordedNo published record——
AbaloparatideCanadaHealth CanadaNot recordedNot recordedNo published record——
AbaloparatideAustraliaTGANot recordedNot recordedNo published record——
AbaloparatideJapanPMDA / MHLWNot recordedNot recordedNo published record——
AbaloparatideChinaNMPANot recordedNot recordedNo published record——
AbaloparatideSport (WADA)WADANot recordedNot recordedNo published record——
AfamelanotideUnited KingdomMHRANot recordedNot recordedNo published record——
AfamelanotideCanadaHealth CanadaNot recordedNot recordedNo published record——
AfamelanotideAustraliaTGANot recordedNot recordedNo published record——
AfamelanotideJapanPMDA / MHLWNot recordedNot recordedNo published record——
AfamelanotideChinaNMPANot recordedNot recordedNo published record——
AfamelanotideSport (WADA)WADANot recordedNot recordedNo published record——
BPC-157United KingdomMHRANot recordedNot recordedNo published record——
BPC-157CanadaHealth CanadaNot recordedNot recordedNo published record——
BPC-157AustraliaTGANot recordedNot recordedNo published record——
BPC-157JapanPMDA / MHLWNot recordedNot recordedNo published record——
BPC-157ChinaNMPANot recordedNot recordedNo published record——
BPC-157Sport (WADA)WADANot recordedNot recordedNo published record——
BivalirudinUnited KingdomMHRANot recordedNot recordedNo published record——
BivalirudinCanadaHealth CanadaNot recordedNot recordedNo published record——
BivalirudinAustraliaTGANot recordedNot recordedNo published record——
BivalirudinJapanPMDA / MHLWNot recordedNot recordedNo published record——
BivalirudinChinaNMPANot recordedNot recordedNo published record——
BivalirudinSport (WADA)WADANot recordedNot recordedNo published record——
BremelanotideUnited KingdomMHRANot recordedNot recordedNo published record——
BremelanotideCanadaHealth CanadaNot recordedNot recordedNo published record——
BremelanotideAustraliaTGANot recordedNot recordedNo published record——
BremelanotideJapanPMDA / MHLWNot recordedNot recordedNo published record——
BremelanotideChinaNMPANot recordedNot recordedNo published record——
BremelanotideSport (WADA)WADANot recordedNot recordedNo published record——
CJC-1295United KingdomMHRANot recordedNot recordedNo published record——
CJC-1295CanadaHealth CanadaNot recordedNot recordedNo published record——
CJC-1295AustraliaTGANot recordedNot recordedNo published record——
CJC-1295JapanPMDA / MHLWNot recordedNot recordedNo published record——
CJC-1295ChinaNMPANot recordedNot recordedNo published record——
CJC-1295Sport (WADA)WADANot recordedNot recordedNo published record——
CagrilintideUnited KingdomMHRANot recordedNot recordedNo published record——
CagrilintideCanadaHealth CanadaNot recordedNot recordedNo published record——
CagrilintideAustraliaTGANot recordedNot recordedNo published record——
CagrilintideJapanPMDA / MHLWNot recordedNot recordedNo published record——
CagrilintideChinaNMPANot recordedNot recordedNo published record——
CagrilintideSport (WADA)WADANot recordedNot recordedNo published record——
CarbetocinUnited StatesFDANot recordedNot recordedNo published record——
CarbetocinEuropean UnionEMANot recordedNot recordedNo published record——
CarbetocinUnited KingdomMHRANot recordedNot recordedNo published record——
CarbetocinJapanPMDA / MHLWNot recordedNot recordedNo published record——
CarbetocinChinaNMPANot recordedNot recordedNo published record——
CarbetocinSport (WADA)WADANot recordedNot recordedNo published record——
DesmopressinEuropean UnionEMANot recordedNot recordedNo published record——
DesmopressinUnited KingdomMHRANot recordedNot recordedNo published record——
DesmopressinCanadaHealth CanadaNot recordedNot recordedNo published record——
DesmopressinAustraliaTGANot recordedNot recordedNo published record——
DesmopressinJapanPMDA / MHLWNot recordedNot recordedNo published record——
DesmopressinChinaNMPANot recordedNot recordedNo published record——
DesmopressinSport (WADA)WADANot recordedNot recordedNo published record——
DulaglutideUnited StatesFDANot recordedNot recordedNo published record——
DulaglutideEuropean UnionEMANot recordedNot recordedNo published record——
DulaglutideUnited KingdomMHRANot recordedNot recordedNo published record——
DulaglutideCanadaHealth CanadaNot recordedNot recordedNo published record——
DulaglutideAustraliaTGANot recordedNot recordedNo published record——
DulaglutideJapanPMDA / MHLWNot recordedNot recordedNo published record——
DulaglutideChinaNMPANot recordedNot recordedNo published record——
DulaglutideSport (WADA)WADANot recordedNot recordedNo published record——
ElamipretideUnited KingdomMHRANot recordedNot recordedNo published record——
ElamipretideCanadaHealth CanadaNot recordedNot recordedNo published record——
ElamipretideAustraliaTGANot recordedNot recordedNo published record——
ElamipretideJapanPMDA / MHLWNot recordedNot recordedNo published record——
ElamipretideChinaNMPANot recordedNot recordedNo published record——
ElamipretideSport (WADA)WADANot recordedNot recordedNo published record——
EpitalonUnited KingdomMHRANot recordedNot recordedNo published record——
EpitalonCanadaHealth CanadaNot recordedNot recordedNo published record——
EpitalonAustraliaTGANot recordedNot recordedNo published record——
EpitalonJapanPMDA / MHLWNot recordedNot recordedNo published record——
EpitalonChinaNMPANot recordedNot recordedNo published record——
EpitalonSport (WADA)WADANot recordedNot recordedNo published record——
ExenatideUnited StatesFDANot recordedNot recordedNo published record——
ExenatideEuropean UnionEMANot recordedNot recordedNo published record——
ExenatideUnited KingdomMHRANot recordedNot recordedNo published record——
ExenatideCanadaHealth CanadaNot recordedNot recordedNo published record——
ExenatideAustraliaTGANot recordedNot recordedNo published record——
ExenatideJapanPMDA / MHLWNot recordedNot recordedNo published record——
ExenatideChinaNMPANot recordedNot recordedNo published record——
ExenatideSport (WADA)WADANot recordedNot recordedNo published record——
GHK-CuUnited StatesFDANot recordedNot recordedNo published record——
GHK-CuEuropean UnionEMANot recordedNot recordedNo published record——
GHK-CuUnited KingdomMHRANot recordedNot recordedNo published record——
GHK-CuCanadaHealth CanadaNot recordedNot recordedNo published record——
GHK-CuAustraliaTGANot recordedNot recordedNo published record——
GHK-CuJapanPMDA / MHLWNot recordedNot recordedNo published record——
GHK-CuChinaNMPANot recordedNot recordedNo published record——
GHK-CuSport (WADA)WADANot recordedNot recordedNo published record——
GHRP-2United KingdomMHRANot recordedNot recordedNo published record——
GHRP-2CanadaHealth CanadaNot recordedNot recordedNo published record——
GHRP-2AustraliaTGANot recordedNot recordedNo published record——
GHRP-2JapanPMDA / MHLWNot recordedNot recordedNo published record——
GHRP-2ChinaNMPANot recordedNot recordedNo published record——
GHRP-2Sport (WADA)WADANot recordedNot recordedNo published record——
GHRP-6United KingdomMHRANot recordedNot recordedNo published record——
GHRP-6CanadaHealth CanadaNot recordedNot recordedNo published record——
GHRP-6AustraliaTGANot recordedNot recordedNo published record——
GHRP-6JapanPMDA / MHLWNot recordedNot recordedNo published record——
GHRP-6ChinaNMPANot recordedNot recordedNo published record——
GHRP-6Sport (WADA)WADANot recordedNot recordedNo published record——
GlucagonUnited KingdomMHRANot recordedNot recordedNo published record——
GlucagonCanadaHealth CanadaNot recordedNot recordedNo published record——
GlucagonAustraliaTGANot recordedNot recordedNo published record——
GlucagonJapanPMDA / MHLWNot recordedNot recordedNo published record——
GlucagonChinaNMPANot recordedNot recordedNo published record——
GlucagonSport (WADA)WADANot recordedNot recordedNo published record——
HexarelinUnited KingdomMHRANot recordedNot recordedNo published record——
HexarelinCanadaHealth CanadaNot recordedNot recordedNo published record——
HexarelinAustraliaTGANot recordedNot recordedNo published record——
HexarelinJapanPMDA / MHLWNot recordedNot recordedNo published record——
HexarelinChinaNMPANot recordedNot recordedNo published record——
HexarelinSport (WADA)WADANot recordedNot recordedNo published record——
Human chorionic gonadotropin (hCG)United KingdomMHRANot recordedNot recordedNo published record——
Human chorionic gonadotropin (hCG)CanadaHealth CanadaNot recordedNot recordedNo published record——
Human chorionic gonadotropin (hCG)AustraliaTGANot recordedNot recordedNo published record——
Human chorionic gonadotropin (hCG)JapanPMDA / MHLWNot recordedNot recordedNo published record——
Human chorionic gonadotropin (hCG)ChinaNMPANot recordedNot recordedNo published record——
Human chorionic gonadotropin (hCG)Sport (WADA)WADANot recordedNot recordedNo published record——
HumaninUnited KingdomMHRANot recordedNot recordedNo published record——
HumaninCanadaHealth CanadaNot recordedNot recordedNo published record——
HumaninAustraliaTGANot recordedNot recordedNo published record——
HumaninJapanPMDA / MHLWNot recordedNot recordedNo published record——
HumaninChinaNMPANot recordedNot recordedNo published record——
HumaninSport (WADA)WADANot recordedNot recordedNo published record——
IpamorelinUnited KingdomMHRANot recordedNot recordedNo published record——
IpamorelinCanadaHealth CanadaNot recordedNot recordedNo published record——
IpamorelinAustraliaTGANot recordedNot recordedNo published record——
IpamorelinJapanPMDA / MHLWNot recordedNot recordedNo published record——
IpamorelinChinaNMPANot recordedNot recordedNo published record——
IpamorelinSport (WADA)WADANot recordedNot recordedNo published record——
KPVUnited KingdomMHRANot recordedNot recordedNo published record——
KPVCanadaHealth CanadaNot recordedNot recordedNo published record——
KPVAustraliaTGANot recordedNot recordedNo published record——
KPVJapanPMDA / MHLWNot recordedNot recordedNo published record——
KPVChinaNMPANot recordedNot recordedNo published record——
KPVSport (WADA)WADANot recordedNot recordedNo published record——
KisspeptinUnited KingdomMHRANot recordedNot recordedNo published record——
KisspeptinCanadaHealth CanadaNot recordedNot recordedNo published record——
KisspeptinAustraliaTGANot recordedNot recordedNo published record——
KisspeptinJapanPMDA / MHLWNot recordedNot recordedNo published record——
KisspeptinChinaNMPANot recordedNot recordedNo published record——
KisspeptinSport (WADA)WADANot recordedNot recordedNo published record——
Kisspeptin-10United KingdomMHRANot recordedNot recordedNo published record——
Kisspeptin-10CanadaHealth CanadaNot recordedNot recordedNo published record——
Kisspeptin-10AustraliaTGANot recordedNot recordedNo published record——
Kisspeptin-10JapanPMDA / MHLWNot recordedNot recordedNo published record——
Kisspeptin-10ChinaNMPANot recordedNot recordedNo published record——
Kisspeptin-10Sport (WADA)WADANot recordedNot recordedNo published record——
LL-37United KingdomMHRANot recordedNot recordedNo published record——
LL-37CanadaHealth CanadaNot recordedNot recordedNo published record——
LL-37AustraliaTGANot recordedNot recordedNo published record——
LL-37JapanPMDA / MHLWNot recordedNot recordedNo published record——
LL-37ChinaNMPANot recordedNot recordedNo published record——
LL-37Sport (WADA)WADANot recordedNot recordedNo published record——
LanreotideEuropean UnionEMANot recordedNot recordedNo published record——
LanreotideUnited KingdomMHRANot recordedNot recordedNo published record——
LanreotideCanadaHealth CanadaNot recordedNot recordedNo published record——
LanreotideAustraliaTGANot recordedNot recordedNo published record——
LanreotideJapanPMDA / MHLWNot recordedNot recordedNo published record——
LanreotideChinaNMPANot recordedNot recordedNo published record——
LanreotideSport (WADA)WADANot recordedNot recordedNo published record——
LeuprolideEuropean UnionEMANot recordedNot recordedNo published record——
LeuprolideUnited KingdomMHRANot recordedNot recordedNo published record——
LeuprolideCanadaHealth CanadaNot recordedNot recordedNo published record——
LeuprolideAustraliaTGANot recordedNot recordedNo published record——
LeuprolideJapanPMDA / MHLWNot recordedNot recordedNo published record——
LeuprolideChinaNMPANot recordedNot recordedNo published record——
LeuprolideSport (WADA)WADANot recordedNot recordedNo published record——
LinaclotideUnited KingdomMHRANot recordedNot recordedNo published record——
LinaclotideCanadaHealth CanadaNot recordedNot recordedNo published record——
LinaclotideAustraliaTGANot recordedNot recordedNo published record——
LinaclotideJapanPMDA / MHLWNot recordedNot recordedNo published record——
LinaclotideChinaNMPANot recordedNot recordedNo published record——
LinaclotideSport (WADA)WADANot recordedNot recordedNo published record——
LiraglutideUnited StatesFDANot recordedNot recordedNo published record——
LiraglutideEuropean UnionEMANot recordedNot recordedNo published record——
LiraglutideUnited KingdomMHRANot recordedNot recordedNo published record——
LiraglutideCanadaHealth CanadaNot recordedNot recordedNo published record——
LiraglutideAustraliaTGANot recordedNot recordedNo published record——
LiraglutideJapanPMDA / MHLWNot recordedNot recordedNo published record——
LiraglutideChinaNMPANot recordedNot recordedNo published record——
LiraglutideSport (WADA)WADANot recordedNot recordedNo published record——
MOTS-cUnited KingdomMHRANot recordedNot recordedNo published record——
MOTS-cCanadaHealth CanadaNot recordedNot recordedNo published record——
MOTS-cAustraliaTGANot recordedNot recordedNo published record——
MOTS-cJapanPMDA / MHLWNot recordedNot recordedNo published record——
MOTS-cChinaNMPANot recordedNot recordedNo published record——
MOTS-cSport (WADA)WADANot recordedNot recordedNo published record——
MazdutideEuropean UnionEMANot recordedNot recordedNo published record——
MazdutideUnited KingdomMHRANot recordedNot recordedNo published record——
MazdutideCanadaHealth CanadaNot recordedNot recordedNo published record——
MazdutideAustraliaTGANot recordedNot recordedNo published record——
MazdutideJapanPMDA / MHLWNot recordedNot recordedNo published record——
MazdutideSport (WADA)WADANot recordedNot recordedNo published record——
Melanotan IIUnited KingdomMHRANot recordedNot recordedNo published record——
Melanotan IICanadaHealth CanadaNot recordedNot recordedNo published record——
Melanotan IIAustraliaTGANot recordedNot recordedNo published record——
Melanotan IIJapanPMDA / MHLWNot recordedNot recordedNo published record——
Melanotan IIChinaNMPANot recordedNot recordedNo published record——
Melanotan IISport (WADA)WADANot recordedNot recordedNo published record——
OctreotideEuropean UnionEMANot recordedNot recordedNo published record——
OctreotideUnited KingdomMHRANot recordedNot recordedNo published record——
OctreotideCanadaHealth CanadaNot recordedNot recordedNo published record——
OctreotideAustraliaTGANot recordedNot recordedNo published record——
OctreotideJapanPMDA / MHLWNot recordedNot recordedNo published record——
OctreotideChinaNMPANot recordedNot recordedNo published record——
OctreotideSport (WADA)WADANot recordedNot recordedNo published record——
OxytocinEuropean UnionEMANot recordedNot recordedNo published record——
OxytocinUnited KingdomMHRANot recordedNot recordedNo published record——
OxytocinCanadaHealth CanadaNot recordedNot recordedNo published record——
OxytocinAustraliaTGANot recordedNot recordedNo published record——
OxytocinJapanPMDA / MHLWNot recordedNot recordedNo published record——
OxytocinChinaNMPANot recordedNot recordedNo published record——
OxytocinSport (WADA)WADANot recordedNot recordedNo published record——
PemvidutideUnited KingdomMHRANot recordedNot recordedNo published record——
PemvidutideCanadaHealth CanadaNot recordedNot recordedNo published record——
PemvidutideAustraliaTGANot recordedNot recordedNo published record——
PemvidutideJapanPMDA / MHLWNot recordedNot recordedNo published record——
PemvidutideChinaNMPANot recordedNot recordedNo published record——
PemvidutideSport (WADA)WADANot recordedNot recordedNo published record——
PramlintideUnited KingdomMHRANot recordedNot recordedNo published record——
PramlintideCanadaHealth CanadaNot recordedNot recordedNo published record——
PramlintideAustraliaTGANot recordedNot recordedNo published record——
PramlintideJapanPMDA / MHLWNot recordedNot recordedNo published record——
PramlintideChinaNMPANot recordedNot recordedNo published record——
PramlintideSport (WADA)WADANot recordedNot recordedNo published record——
RetatrutideUnited KingdomMHRANot recordedNot recordedNo published record——
RetatrutideCanadaHealth CanadaNot recordedNot recordedNo published record——
RetatrutideAustraliaTGANot recordedNot recordedNo published record——
RetatrutideJapanPMDA / MHLWNot recordedNot recordedNo published record——
RetatrutideChinaNMPANot recordedNot recordedNo published record——
RetatrutideSport (WADA)WADANot recordedNot recordedNo published record——
SelankUnited KingdomMHRANot recordedNot recordedNo published record——
SelankCanadaHealth CanadaNot recordedNot recordedNo published record——
SelankAustraliaTGANot recordedNot recordedNo published record——
SelankJapanPMDA / MHLWNot recordedNot recordedNo published record——
SelankChinaNMPANot recordedNot recordedNo published record——
SelankSport (WADA)WADANot recordedNot recordedNo published record——
SemaglutideUnited KingdomMHRANot recordedNot recordedNo published record——
SemaglutideCanadaHealth CanadaNot recordedNot recordedNo published record——
SemaglutideAustraliaTGANot recordedNot recordedNo published record——
SemaglutideJapanPMDA / MHLWNot recordedNot recordedNo published record——
SemaglutideChinaNMPANot recordedNot recordedNo published record——
SemaglutideSport (WADA)WADANot recordedNot recordedNo published record——
SemaxUnited KingdomMHRANot recordedNot recordedNo published record——
SemaxCanadaHealth CanadaNot recordedNot recordedNo published record——
SemaxAustraliaTGANot recordedNot recordedNo published record——
SemaxJapanPMDA / MHLWNot recordedNot recordedNo published record——
SemaxChinaNMPANot recordedNot recordedNo published record——
SemaxSport (WADA)WADANot recordedNot recordedNo published record——
SurvodutideUnited StatesFDANot recordedNot recordedNo published record——
SurvodutideEuropean UnionEMANot recordedNot recordedNo published record——
SurvodutideUnited KingdomMHRANot recordedNot recordedNo published record——
SurvodutideCanadaHealth CanadaNot recordedNot recordedNo published record——
SurvodutideAustraliaTGANot recordedNot recordedNo published record——
SurvodutideJapanPMDA / MHLWNot recordedNot recordedNo published record——
SurvodutideChinaNMPANot recordedNot recordedNo published record——
SurvodutideSport (WADA)WADANot recordedNot recordedNo published record——
TB-500United KingdomMHRANot recordedNot recordedNo published record——
TB-500CanadaHealth CanadaNot recordedNot recordedNo published record——
TB-500AustraliaTGANot recordedNot recordedNo published record——
TB-500JapanPMDA / MHLWNot recordedNot recordedNo published record——
TB-500ChinaNMPANot recordedNot recordedNo published record——
TB-500Sport (WADA)WADANot recordedNot recordedNo published record——
TeduglutideUnited KingdomMHRANot recordedNot recordedNo published record——
TeduglutideCanadaHealth CanadaNot recordedNot recordedNo published record——
TeduglutideAustraliaTGANot recordedNot recordedNo published record——
TeduglutideJapanPMDA / MHLWNot recordedNot recordedNo published record——
TeduglutideChinaNMPANot recordedNot recordedNo published record——
TeduglutideSport (WADA)WADANot recordedNot recordedNo published record——
TeriparatideEuropean UnionEMANot recordedNot recordedNo published record——
TeriparatideUnited KingdomMHRANot recordedNot recordedNo published record——
TeriparatideCanadaHealth CanadaNot recordedNot recordedNo published record——
TeriparatideAustraliaTGANot recordedNot recordedNo published record——
TeriparatideJapanPMDA / MHLWNot recordedNot recordedNo published record——
TeriparatideChinaNMPANot recordedNot recordedNo published record——
TeriparatideSport (WADA)WADANot recordedNot recordedNo published record——
TesamorelinEuropean UnionEMANot recordedNot recordedNo published record——
TesamorelinUnited KingdomMHRANot recordedNot recordedNo published record——
TesamorelinCanadaHealth CanadaNot recordedNot recordedNo published record——
TesamorelinAustraliaTGANot recordedNot recordedNo published record——
TesamorelinJapanPMDA / MHLWNot recordedNot recordedNo published record——
TesamorelinChinaNMPANot recordedNot recordedNo published record——
TesamorelinSport (WADA)WADANot recordedNot recordedNo published record——
Thymosin alpha-1United KingdomMHRANot recordedNot recordedNo published record——
Thymosin alpha-1CanadaHealth CanadaNot recordedNot recordedNo published record——
Thymosin alpha-1AustraliaTGANot recordedNot recordedNo published record——
Thymosin alpha-1JapanPMDA / MHLWNot recordedNot recordedNo published record——
Thymosin alpha-1ChinaNMPANot recordedNot recordedNo published record——
Thymosin alpha-1Sport (WADA)WADANot recordedNot recordedNo published record——
Thymosin beta-4United KingdomMHRANot recordedNot recordedNo published record——
Thymosin beta-4CanadaHealth CanadaNot recordedNot recordedNo published record——
Thymosin beta-4AustraliaTGANot recordedNot recordedNo published record——
Thymosin beta-4JapanPMDA / MHLWNot recordedNot recordedNo published record——
Thymosin beta-4ChinaNMPANot recordedNot recordedNo published record——
Thymosin beta-4Sport (WADA)WADANot recordedNot recordedNo published record——
TirzepatideUnited KingdomMHRANot recordedNot recordedNo published record——
TirzepatideCanadaHealth CanadaNot recordedNot recordedNo published record——
TirzepatideAustraliaTGANot recordedNot recordedNo published record——
TirzepatideJapanPMDA / MHLWNot recordedNot recordedNo published record——
TirzepatideChinaNMPANot recordedNot recordedNo published record——
TirzepatideSport (WADA)WADANot recordedNot recordedNo published record——
VasopressinEuropean UnionEMANot recordedNot recordedNo published record——
VasopressinUnited KingdomMHRANot recordedNot recordedNo published record——
VasopressinAustraliaTGANot recordedNot recordedNo published record——
VasopressinJapanPMDA / MHLWNot recordedNot recordedNo published record——
VasopressinChinaNMPANot recordedNot recordedNo published record——
VasopressinSport (WADA)WADANot recordedNot recordedNo published record——
ZiconotideUnited KingdomMHRANot recordedNot recordedNo published record——
ZiconotideCanadaHealth CanadaNot recordedNot recordedNo published record——
ZiconotideAustraliaTGANot recordedNot recordedNo published record——
ZiconotideJapanPMDA / MHLWNot recordedNot recordedNo published record——
ZiconotideChinaNMPANot recordedNot recordedNo published record——
ZiconotideSport (WADA)WADANot recordedNot recordedNo published record——